TP53 and breast cancer: Two cancer cell lines of different origin (HCT116 and MCF7, colon and breast cancer, respectively) with wild-type p53 were treated with Ligand (50 and 100 μM), Complex (50 μM), CuCl2 (50 μM), and doxorubicin (4 μM) for 72 h, during this period the cytotoxic response kinetics were monitored in real time.